NCT02807961View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

PHASE1TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

May 31, 2017

Conditions
Genetic DiseasesNonsense Mutations
Interventions
DRUG

ELX-02

Synthetic aminoglycoside

DRUG

Placebo

Placebo comparator

Sponsors
All Listed Sponsors
lead

Eloxx Pharmaceuticals, Inc.

INDUSTRY

NCT02807961 - Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter